RDB07832 - pGL3-AID R2 del.-03

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Terms and conditions set forth by the DEPOSITOR	In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature(s) designated by the DEPOSITOR is requested. (Nat. Immunol., 11, 148-154 (2010)). In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE.
Additional terms and conditions for distribution	The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.
Ordering	Please visit Information of Request for Distribution.[link] Order form [Credit Card Payment] [Bank Transfer Payment] Material Transfer Agreement (MTA for use for not-for-profit academic purpose) [Word]

提供案内 (日本国内)

[open/close]

提供条件	利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する (Nat. Immunol., 11, 148-154 (2010))。利用者は、研究成果の公表にあたって謝辞の表明を必要とする。　学術機関の学術研究に限る。　営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。　利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。
付加的提供条件	本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。
提供依頼	手続きの詳細は、「提供申込みについて[link]」をご覧ください。提供依頼書 [Word] 提供同意書 (MTA、非営利機関による非営利学術研究用)[Word]

References and tips

Sequence information

Catalog #	Resource name	Shipping form	Fee (non-profit org.)
RDB07832	pGL3-AID R2 del.-03	DNA solution

original	Tran, T.H., B cell-specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of silencers. Nat. Immunol., 11, 148-154 (2010). PMID 19966806.

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check

icon as well as clone information before placing your order.

Primer: ME-1290Rv Sequence file: RDB07832_A4Gia.seq
>07832_07832_A4Gi_ME_1290Rv_B12_06.ab1 1 ATGGCATTTC ATTTTATGTT TCAGGTTCAG GGGGAGGTGT GGGAGGTTTT TTAAAGCAAG 61 TAAAACCTCT ACAAATGTGG TAAAATCGAT AAGGGATCCG CAGGGTGTTC TTCAGATTCC 121 AGATTTTTCC TTTCTTGTCT TCCTTCTTTC TTTTTGTTAC CCTTCTCCTA CCCCCTCTTC 181 TTCTCCCCCT CCTCCTCTTC CTCCCTCCTC CCCATCTCTT CCCCTCCTCT TCTCCCTCCT 241 CCCCCTCCTC TTCCCCTTCT CCTCTTCCCC CTCTTCCTCC TCTTCCTCCT CCTTCTCCTG 301 CTCCCCATCT CTTTCCCTCC TCTTCTCCCT CCTCCTCCTC CTTTTGCCCC TTCTCCTCTT 361 CCCCCTCCTC CTCTTCCTTT TCCTTCTCCT CCTTCTCCTC CCCCCTCTCC TCCCCCTTTC 421 CTCCTCCCAC TCTCCCTCAC CCCTATCAGG GACCACATTG AAGACCTCAC ACATGCTAGA 481 CAAGTAATCT GCCACTTAAT TACATCCTGA GCCCTCAAAA AGCAAACAGA CAGACAGACA 541 GACAGACAGA CAGACAGACA AACAAACAAA TGTTCACAGG AGGCAGGCAG ACAGCCTGAG 601 CTGCTTCTGG GTTTATAGTG AATTTTGAAA CCAAATCTGA GATCTATGTC CTGATGGAGA 661 AGGGTCCGAG AGAAATGCAT GAGCATGGCA AAATGCAAAG CAAAGACGAG GCTGAGATTC 721 AGGGAGAAGC AAACAAGACA GTGGAGAGAC ACAGGATGGC ACGGCACGGA CTGGAGCAAG 781 GGCAGCGAGT AACTCAAGGC AGCCCTGCTA CTAGGCTGGG ATTATTTTTA ACCCCTTGAG 841 TCTGGTTTGC ATTGCTGGGG AAGCAGCTAA GGTTCTGCCT CAAGGAGCAC AGCTGTCTCA 901 GCAGCTGGCG ATCTACAGGT TTGGGACACC ACCTAGCAAA GTCCCTCCCT TACCGGGAGG 961 GACATCCCCG AGGAGAGGGA GCTGGAAATA GGCTCCTAGC TAGAGTTGAG GGGGGATCCG 1021 TCGACCGATG CCCTTTGAGA GCCTTTCAAC CCAGTCAGCT CCTTCCTGGT GGGGCGCGGG 1081 GGCATGACTA TCGTCGCCCG CACTTATGAC TGTCATTCGT TATCATGCAA CTTCGTAAGA 1141 CAGATGCCCG GCAGCGCCTT CTTTTACCGG CCATTGCGCT GTCGGCTTTC AACT //
Primer: pGL3_RV4 Sequence file: RDB07832_A4Gib.seq
>07832_07832_A4Gi_Rv4_C12_09.ab1 1 TCAGGACTGA TGGGTTGAGG CTCTCAGGGC ATCGGTCGAC GGATCCCCCC TCAACTCTAG 61 CTAGGAGCCT ATTTCCAGCT CCCTCTCCTC GGGATGTCCC TCCCGGTAAG GAGGACTTTG 121 CTAGGTGGTG TCCCAAACCT GTAGATCGCC AGCTGCTGAG ACAGCTGTGC TCCTTGAGGC 181 AGAACCTTAG CTGCTTCCCC AGCAATGCAA ACCAGACTCA AGGGGTTAAA AATAATCCCA 241 GCCTAGTAGC AGGGCTGCCT TGAGTTACTC GCTGCCCTTG CTCCAGTCCG TGCCGTGCCA 301 TCCTGTGTCT CTCCACTGTC TTGTTTGCTT CTCCCTGAAT CTCAGCCTCG TCTTTGCTTT 361 GCATTTTGCC ATGCTCATGC ATTTCTCTCG GACCCTTCTC CATCAGGACA TAGATCTCAG 421 ATTTGGTTTC AAAATTCACT ATAAACCCAG AAGCAGCTCA GGCTGTCTGC CTGCCTCCTG 481 TGAACATTTG TTTGTTTGTC TGTCTGTCTG TCTGTCTGTC TGTCTGTCTG TTTGCTTTTT 541 GAGGGCTCAG GATGTAATTA AGTGGCAGAT TACTTGTCTA GCATGTGTGA GGTCTTCAAT 601 GTGGTCCCTG ATAGGGGTGA GGGAGAGTGG GAGGAGGAAA GGGGGAGGAG AGGGGGGGAT 661 CCAGAAGGAC GATGACCCTA AAGAGCCATG CAGGAGAGGT CAAGCACCGA TCACGGTGGC 721 AAACGGAGGC ATGAGAGGGA GAAGAGGAGG GAAAGAGATG GGGAGCAGGA GAAGAAGGAG 781 AGAGGAGGAG AGGGGGAAGA GGAGAAGGGA AGAGAGGGGA GGAAGGAGAA GAGGAGGGAA 841 GAAATGGGAA GGAGGGAAGA //

pGL3-AID R2 del.-03

Distribution information

References and tips

Sequence information

References